Clinical trial
Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
NCT06299540 is registered in ClinicalTrials.gov with Janssen Cilag S.A.S. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Benefits of an Individual Physical Activity Intervention on Health-related Quality of Life in Patients With Chronic Lymphocytic Leukemia Receiving Ibrutinib in Real-life Practice
- Lead sponsor
- Janssen Cilag S.A.S.
- Phase
- Observational
- Overall status
- Recruiting
- Start date
- May 27, 2024
- Completion date
- November 30, 2027
- Enrollment
- 180 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.